Asset Details
Do you wish to reserve the book?
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction
Do you wish to request the book?
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction
2022
Overview
Background
Numerous drugs have the potential to be affected by cytochrome P450 (CYP) 2B6-mediated drug–drug interactions (DDIs).
Objectives
In this work, we extend a static approach to the prediction of the extent of pharmacokinetics DDIs between substrates and inhibitors or inducers of CYP2B6.
Methods
This approach is based on the calculation of two parameters (the contribution ratio [CR], representing the fraction of dose of the substrate metabolized via this pathway and the inhibitory or inducing potency of the perpetrator [IR or IC, respectively]) calculated from the area under the concentration–time curve (AUC) ratios obtained in in-vivo DDI studies.
Results
Forty-eight studies involving 5 substrates, 11 inhibitors and 18 inducers of CYP2B6 (overall 15 inhibition and 33 induction studies) were divided into test and validation sets and considered for estimation of the parameters. The proposed approach demonstrated a fair accuracy for predicting the extent of DDI related to CYP2B6 inhibition and induction, all predictions related to the validation test (
N
= 18) being 50–200% of the observed ratios.
Conclusions
This methodology can be used for proposing initial dose adaptations to be adopted, for example in clinical use or for designing DDI studies involving this enzyme.
Publisher
Springer International Publishing,Springer Nature B.V
